ARCUTIS BIOTHERAPEUTICS INC. - COMMON STOCK

12,83

03-марта-25 15:45:00

15 мин. задержка

Акции

-0,86

-6,28%

Сегодняшний диапазон

12,67 - 13,85

ISIN

N/A

Источник

NASDAQ

Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting

28 фев 2025 08:00:00 Источник Nasdaq GlobeNewswire
U.S. FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

26 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

25 фев 2025 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces Publication of Positive Data from INTEGUMENT-PED Trial Evaluating ZORYVE® (roflumilast) Cream 0.05% in Children 2 to 5 Years Old with Mild to Moderate Atopic Dermatitis in Pediatric Dermatology

24 фев 2025 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

18 фев 2025 15:35:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 фев 2025 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

27 янв 2025 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

12 янв 2025 07:30:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 янв 2025 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

16 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

06 дек 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces Promotions on Executive Management Team

03 дек 2024 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

13 ноя 2024 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

06 ноя 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 ноя 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

24 окт 2024 07:00:00 Источник Nasdaq GlobeNewswire
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

23 окт 2024 15:00:00 Источник Nasdaq GlobeNewswire
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

18 окт 2024 07:20:14 Источник Nasdaq GlobeNewswire
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 окт 2024 15:00:00 Источник Nasdaq GlobeNewswire
New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types

25 сен 2024 00:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.